FDA committee votes in favor of Pfizer’s Xeljanz for ulcerative colitis

This article was originally published here

Pfizer has received a positive response from the Gastrointestinal Drugs Advisory Committee (GIDAC) of the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) on Xeljanz (tofacitinib) to treat adult patients with moderately to severely active ulcerative colitis (UC).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply